Table 2.
Select Trials of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC
| Trial NCT Number | Trial Name | Phase | Stage | Treatment | Primary Endpoint | MPR (No. of Patients) | PCR (No. of Patients) |
|---|---|---|---|---|---|---|---|
| NCT03081689 | NADIM | Phase 2 | IIIA | Nivolumab + carboplatin/paclitaxel | PFS | 34/41 (83%) | 26/41 (63%) |
| NCT02716038 | Phase 2 | IB-IIIA | Atezolizumab + cabroplatin/Nab-paclitaxel | MPR | 7/11 (63.6%) | 3/11 (37.3%) | |
| NCT02572843 | SAKK 6/14 | Phase 2 | IIIA | Durvalumab + cisplatin/docetaxel | EFS | 33/55 (60.0%) | 10/55 (18.2%) |
| NCT02998528 | Checkmate 816 | Phase 3 | IB-IIIA | Nivolumab + ipilimumab or nivolumab + chemotherapy | EFS/PCR | Not reported | 24% |
| NCT04304248 | NeoTPD01 | Phase 2 | IIIA-IIIB | Toripalimab + carboplatin/pemetrexed or Nab-paclitaxel | MPR | 20/30 (66.7%) | 15/30 (50%) |
| NCT03838159 | NADIM II | Phase 2 | IIIA-IIIB | Nivolumab + carboplatin/paclitaxel | PCR | Ongoing | Ongoing |
| NCT03871153 | HCRN LUN17-321 | Phase 2 | III | Durvalumab + carboplatin/paclitaxel + radiation | PCR | Ongoing | Ongoing |
| NCT03456063 | IMpower030 | Phase 3 | II–IIIB | Atezolizumab + platinum chemotherapy | MPR and EFS | Ongoing | Ongoing |
| NCT04061590 | Phase 2 | I–IIIA | Pembrolizumab + cisplatin/pemetrexed | % of patients with TIICs | Ongoing | Ongoing |
Abbreviations: MPR, major pathologic response; PCR, pathologic complete response; EFS, event free survival; PFS, progression-free survival; TIIC, tumor infiltrating immune cells.